Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Malignant Pleural Mesothelioma: Recent Advances in Diagnosis, Molecular Characterization, Predictive...
share announcement

Malignant Pleural Mesothelioma: Recent Advances in Diagnosis, Molecular Characterization, Predictive Markers and Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 621

Special Issue Editors

Dr. Giuseppe Marulli

E-Mail Website
Guest Editor
1. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy
2. Thoracic Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy
Interests: lung cancer; mesothelioma and mediastinal tumors; standard minimally invasive surgery (VATS) and robotic surgery; endoscopy and trachea surgery; lung transplantation
Dr. Giuseppe Mangiameli

E-Mail Website
Guest Editor
1. Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20072 Milan, Italy
2. Thoracic Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy
Interests: cancer
Dr. Emanuele Voulaz

E-Mail Website
Guest Editor
Thoracic Surgery, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy
Interests: thoracic surgery; breast surgery

Special Issue Information

Dear Colleagues,

Malignant pleural mesothelioma (MPM) is an aggressive neoplasm, which arises from pleural mesothelial cells of the pleura. It is strictly related to asbestos exposure with a latency time of around 20 to 50 years. The global incidence of MPM has continuously risen along with the widespread industrial use of asbestos. MPM is associated with an extremely poor prognosis, considering that a median survival of less than 1 year and a 5-year survival rate of less than 10% are commonly reported. Several aspects of mesothelioma treatment are discussed, in particular, regarding the extent and best type of surgery, radiotherapy, and the role of neoadjuvant or adjuvant treatment.

Recent progress in research and clinical practice has demonstrated evidence relating to molecular pathogenesis and perspectives on potential therapeutic approaches leading to promising treatment, such as immunotherapy, which could be a favorable option for patients with advanced diseases.

This Special Issue is designated to be a comprehensive review of the state-of-the-art advances in scientific research on mesothelioma, including the pathogenesis, diagnosis, and management of MPM, including, but not limited to:

  • Diagnosis: histological and molecular characteristics;
  • Radiology and tumor response;
  • Oncological management;
  • Surgery;
  • Innovations in radiotherapy;
  • Molecular alterations;
  • Targeted agents;
  • Cellular therapies;
  • Prognostic factors;
  • Further trials of interest and future perspectives.

Dr. Giuseppe Marulli
Dr. Giuseppe Mangiameli
Dr. Emanuele Voulaz
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • mesothelioma
  • pleural disease
  • diagnosis
  • prediction
  • prognosis
  • oncology
  • surgery

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 1623 KiB  
Article
The Incidence of Distant Metastases in Patients with Pleural Mesothelioma Screened for a Multimodal Approach: How Much Staging Do We Really Need?
by Arberit Hyseni, Jan Viehof, Jan Hockmann, Martin Metzenmacher, Wilfried Eberhardt, Ken Herrmann, Hubertus Hautzel, Clemens Aigner and Till Plönes
Cancers 2024, 16(10), 1917; https://doi.org/10.3390/cancers16101917 - 17 May 2024
Viewed by 394
Abstract
Pleural mesothelioma (PM) is a very aggressive malignancy with a poor prognosis. Most patients receive systemic treatment only; however, some patients may benefit from multimodality treatment. A precise staging of patients undergoing multimodal treatment is mandatory. We investigated the pattern of metastasis in [...] Read more.
Pleural mesothelioma (PM) is a very aggressive malignancy with a poor prognosis. Most patients receive systemic treatment only; however, some patients may benefit from multimodality treatment. A precise staging of patients undergoing multimodal treatment is mandatory. We investigated the pattern of metastasis in a cohort of patients screened for multimodal treatment to define the extent of staging examinations. Additionally, we investigated the occurrence of metastasis during follow-up. We investigated a single-center experience of 545 patients newly diagnosed and/or treated with PM between the years 2010 and 2022. Patients who were treated naïvely and had a whole set of imaging of the brain were included and further analyzed. A total of 54% of all patients with cerebral imaging had an available 18FDG-PET CT scan. We also recorded metastasis during treatment follow-up. There were 110 patients who had a whole set of imaging (CT = 89% and MRI = 11%) of the brain, and 54% of all patients with cerebral imaging had an available 18FDG-PET CT scan. We identified four patients with cerebral metastasis at the time of first diagnosis, which means that 5.4% of the cohort had cerebral metastasis and 13.3% of all patients in the subgroup with complete data of 18FDG-PET CT had distant non-cerebral metastasis. During the longitudinal follow-up, we found 11 patients with newly diagnosed metastases after a median time of 1.6 years (range: 2 months to 3.3 years) after first diagnosis without metastases. Distant metastases are more frequent in mesothelioma patients than previously thought. This implies that extensive staging is needed for patients selected for multimodal treatment, including brain imaging and 18FDG-PET CT. Full article
(This article belongs to the Special Issue Malignant Pleural Mesothelioma: Recent Advances in Diagnosis, Molecular Characterization, Predictive Markers and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop